PHARMACYCLICS INC (PCYC)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Robert W. Duggan
Employees:
607
PHARMACYCLICS INC, 995 E ARQUES AVE, SUNNYVALE, CA 94085-4521
408 774 0330

• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Pharmacyclics, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for the treatment of cancer and immune-mediated diseases in the United States.

Data derived from most recent annual or quarterly report
Market Cap 20.062 Trillion Shares Outstanding76.792 Billion Avg 30-day Volume 765.284 Thousand
P/E Ratio281.6708 Dividend Yield0.0 EPS0.95
Price to Revenue24.8482 Debt to Equity0.0 EBITDA112.8 Million
Price to Book Value22.7175 Operating Margin13.225600000000002 Enterprise Value19.393 Billion
Current Ratio5.537 EPS Growth-0.164 Quick Ratio4.951
1 Yr BETA 0.6857 52-week High/Low 0.0 / Profit Margin8.8217
Operating Cash Flow Growth-14.4517 Altman Z-Score54.9114 Free Cash Flow to Firm 39.968 Million
View SEC Filings from PCYC instead.

View recent insider trading info

PHARMACYCLICS INC YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding PCYC (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding PCYC

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

DUGGAN ROBERT W CHAIRMAN AND CEO

  • Officer
  • Director
  • 10% Owner
 0 2015-05-26 0

HALVORSON ERIC H

  • Director
 0 2015-05-26 0

VAN DEN BROEK RICHARD

  • Director
 0 2015-05-26 0

MEHTA MINESH

  • Director
 0 2015-05-26 0

SMITH DAVID DUANE

  • Director
 0 2015-05-26 0

BOOTH ROBERT F.

  • Director
 0 2015-05-26 0

ZANGANEH MAKY CHIEF OPERATING OFFICER

  • Officer
 0 2015-05-26 0

TAN HEOW CHIEF QUALITY&TECH OPERATIONS

  • Officer
 0 2015-05-26 0

CLARK KENNETH A

  • Director
 0 2015-05-26 0

SONI MANMEET SINGH CHIEF FINANCIAL OFFICER

  • Officer
 0 2015-05-26 0

TOMASELLO SHAWN CHIEF COMMERCIAL OFFICER

  • Officer
 0 2015-05-26 0

FARDIS MARIA CHIEF OF ONCOLOGY OPS & ALLIAN

  • Officer
 3,193 2014-11-13 0

LOVE RICHARD B GENERAL COUNSEL

  • Officer
 205 2014-11-10 0

MCGREIVY JESSE CHIEF MEDICAL OFFICER

  • Officer
 0 2014-08-07 0

BARI SAMINA SVP, CORP COMMUNICATIONS

  • Officer
 0 2014-07-07 0

SJOVALL BOULTBEE PAULA S EVP, SALES AND MARKETING

  • Officer
 12,585 2014-05-08 0

ERDTMANN RAINER M SR. VP, IR AND ADMIN

  • Officer
 5,701 2014-04-30 0

OUTTEN MATTHEW VP, COMMERCIAL OPERATIONS

  • Officer
 10,938 2014-04-30 0

HEMMI GREGORY SR. VP CHEMICAL OPERATIONS

  • Officer
 No longer subject to file 2014-03-05 0

CHANG BETTY Y VP, RESEARCH/BIOLOGY

  • Officer
 No longer subject to file 2014-03-04 0

LOURY DAVID J EXECUTIVE VP, TOXICOLOGY

  • Officer
 1,628 2013-10-31 0

CRUM MICHAEL VICE PRESIDENT, U.S. SALES

  • Officer
 327 2013-10-31 0

LEE DANA VP, CLINICAL DRUG SAFETY

  • Officer
 231 2013-10-31 0

FAUST ELIZABETH VP MEDICAL AFFAIRS

  • Officer
 327 2013-10-31 0

SUCHET CHRISTOPHER VP INFORMATION TECHNOLOGY

  • Officer
 327 2013-10-31 0

RAY SUMITA CHIEF COMPLIANCE OFFICER

  • Officer
 112 2013-10-31 0

GRAEF THORSTEN VP, CLINICAL SCIENCE

  • Officer
 806 2013-10-31 0

BEAUPRE DARRIN VP, CLIN. MED. & EARLY DEV.

  • Officer
 386 2013-10-31 0

SHEARER SCOTT T VP, GLOBAL QUALITY

  • Officer
 0 2013-06-06 0

BOEHM KENNETH F. SVP, HUMAN RESOURCES

  • Officer
 0 2013-05-13 0

CLOW FONG WANG VP BIOSTATISTICS DATA MGMT

  • Officer
 4,024 2013-04-30 0

BUGGY JOSEPH J VP, RESEARCH

  • Officer
 8,713 2013-04-30 0

KUNKEL LORI ANNE CHIEF MEDICAL OFFICER

  • Officer
 2,842 2013-04-30 0

GAYKO URTE SR. VP, REGULATORY

  • Officer
 406 2013-04-30 0

HUH CHRISTINE VP, HUMAN RESOURCES

  • Officer
 4,921 2012-10-31 0

BRUMM JOSHUA T EVP, FINANCE

  • Officer
 0 2012-10-26 0

HARDIMAN ROY C.

  • Director
 0 2012-10-01 0

ANDERSON CYNTHIA VP, CLINICAL OPERATIONS

  • Officer
 0 2012-09-24 0

ASBURY MARK VP AND GENERAL COUNSEL

  • Officer
 1,427 2012-04-30 0

BAKER BIOTECH CAPITAL (GP), LLC

BAKER FELIX

BAKER JULIAN

  • 10% Owner
 557,211 2012-02-10 0

BAKER BROTHERS LIFE SCIENCES CAPITAL (GP), LLC

BAKER FELIX

BAKER JULIAN

  • 10% Owner
 8,574,445 2012-01-24 0

14159 CAPITAL (GP), LLC

BAKER FELIX

BAKER JULIAN

  • 10% Owner
 195,858 2012-01-24 0

HEDRICK ERIC VICE PRESIDENT

  • Officer
 4,152 2011-12-02 0

FYFE GWEN A.

  • Director
 0 2011-10-03 0

HAMDY AHMED MD CHIEF MEDICAL OFFICER

  • Officer
 11,966 2011-04-29 0

ADELMAN JASON T

  • Director
 0 2010-10-01 0

RICE GLENN C

  • Director
 0 2010-10-01 0

BAMDAD CYNTHIA

  • Director
 0 2010-10-01 0

KNIGHTON JAMES L

  • Director
 0 2008-12-12 0

LEVY RICHARD M

  • Director
 0 2008-10-01 0

GILBURNE MILES R

  • Director
 140,000 2008-10-01 0

WHITE CHRISTINE ANNA

  • Director
 0 2008-10-01 0

LOWDER JAMES N MD VP CLINICAL DEVELOPMENT

  • Officer
 0 2008-07-24 0

LEA LEIV VP FIN & ADMIN & CFO

  • Officer
 20,893 2008-04-30 0

MILLER RICHARD A MD PRES, CEO & DIRECTOR

  • Officer
  • Director
 326,798 2008-03-18 0

ROHN WILLIAM R

  • Director
 0 2008-01-02 0

INOUYE MICHAEL K SR. VP, CORP & COMM DEV.

  • Officer
 0 2007-06-06 0

RENSCHLER MARKUS MD SR. VP, ONCOLOGY CLINICAL DEV

  • Officer
 66,394 2007-03-13 0

PHAN SEE CHUN MD VICE PRESIDENT

  • Officer
 35,151 2007-03-13 0

ITRI LORETTTA M

  • Director
 3,333 2006-04-03 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

No recent transactions

*** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

Elevate your investments